1. IDH Inhibitors in AML

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Cytogenetic and Mutational Landscape of AML

4. IDH Mutations as a Target in AML

5. Current Status of IDH Inhibitors

6. Exposure to Mutated IDH1 Inhibitor Effectively Inhibits the Oncometabolite 2-HG

7. Enasidenib in R/R AML Phase 1/2 Study Design[a] and Updated Results[b]

8. Evolution of Response With Enasidenib

9. Enasidenib in R/R AML: Overall Survival

10. Phase 1 Study of Ivosidenib in IDH1-Mutant R/R AML

11. Ivosidenib in IDH1-Mutant R/R AML

12. Impact of IDH1 Mutation Clearance Status With Ivosidenib

13. IDH Inhibitor Toxicities

14. IDH Inhibitor Toxicities

15. Identification and Treatment of Clinical IDH-Differentiation Syndrome

16. Indirect Hyperbilirubinemia With Enasidenib

17. QT Prolongation With Ivosidenib

18. Phase 1 Study of Induction + Enasidenib/Ivosidenib Study Design

19. Phase 1 Study of Induction + Enasidenib/Ivosidenib Best Responses

20. Phase 1 Study of Induction + Enasidenib/Ivosidenib Overall Survival

21. HOVON 150AML Study Design

22. Ivosidenib or Enasidinib With Azacitidine for Unfit Patients With ND AML

23. Ivosidenib + AZA Treatment Duration, Response, and Disposition

24. Frontline Study of AZA ± Ivosidenib

25. Incorporating IDH Mutation Testing in the Clinic

26. Impact of Co-Occurring Mutations at Start of Enasidinib

27. No Apparent Impact of IDH VAF on Likelihood of Response

28. Clinical Role of IDH Inhibitors Today

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)